<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;First-trimester abortion in women with medical conditions.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Guiahi M, Davis A, Society of Family Planning. First-trimester abortion in women with medical conditions. Contraception. 2012 Dec;86(6):622-30. [56 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23039921&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus of mother, complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication  (648.03); Human immunodeficiency virus [HIV] disease  (042); Obesity, unspecified  (278.00); Unspecified disorder of thyroid  (246.9); Von Willebrand's disease  (286.4)"/><FieldValue Value="MSH: Abortifacient Agents ; Abortion, Legal ; Ambulatory Care ; Antibiotic Prophylaxis ; Anticoagulants ; Asthma ; Epilepsy ; HIV Infections ; Hospitalization ; Hypertension ; Medication Therapy Management ; Mifepristone ; Obesity ; Pregnancy ; Pregnancy Complications ; Pregnancy in Diabetics ; Pregnancy Trimester, First ; Pregnancy, Unwanted ; Thyroid Diseases ; von Willebrand Diseases "/><FieldValue Value="MTH: ambulatory care services ; Antibiotic Prophylaxis ; Anticoagulants ; Anticoagulation Therapy ; Asthma ; Epilepsy ; HIV Infections ; Hospitalization ; Hypertensive disease ; Legal abortion (procedure) ; Medical abortion (procedure) ; Obesity ; Pregnancy ; Pregnancy Complications ; Pregnancy in Diabetics ; Thyroid Diseases ; Unwanted pregnancy ; von Willebrand Disease "/><FieldValue Value="PDQ: anticoagulation ; mifepristone ; obesity "/><FieldValue Value="SNOMEDCT_US: Abortifacient preparation  (6716006); Antibiotic prophylaxis  (422181004); Anticoagulant  (372862008); Anticoagulant  (81839001); Asthma  (195967001); Disorder of thyroid gland  (14304000); Epilepsy  (128613002); Epilepsy  (313307000); Epilepsy  (84757009); First trimester pregnancy  (255246003); First trimester pregnancy  (57630001); Human immunodeficiency virus infection  (86406008); Hypertensive disorder  (38341003); Inpatient care  (394656005); Medical termination of pregnancy  (285409006); Mifepristone  (129483007); Mifepristone  (395796009); Obesity  (414915002); Obesity  (414916001); Pregnancy  (289908002); Unwanted pregnancy  (58532003); von Willebrand disorder  (128105004)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Unwanted pregnancy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Co-existing medical conditions, including diabetes, hypertension, obesity, human immunodeficiency virus (HIV) infection, asthma, epilepsy, thyroid disease, and von Willebrand disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Anesthesiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Hematology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To review the medical literature evaluating common approaches of providing first-trimester abortion care to women with coexisting medical conditions&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Women with medical conditions undergoing a first-trimester abortion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Considerations for hospital-based abortion care versus outpatient care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Choice of surgical abortion or medication abortion &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considerations for use of mifepristone, including contraindications for use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Special issues related to use of routine abortion medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considerations for common chronic conditions including diabetes, hypertension, obesity, human immunodeficiency virus (HIV) infection, asthma, epilepsy, thyroid disease, and von Willebrand disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anticoagulation management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of additional antibiotics at the time of abortion for high-risk patients to prevent infective endocarditis (not recommended) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk for adverse health events during pregnancy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The authors used the PubMed database to identify publications related to first-trimester abortion and coexisting medical conditions between 1981 and 2011. They also identified articles related to medical problems in the context of general health, perioperative guidelines and pregnancy. In addition, the references of publications found through these databases were reviewed to capture any additional articles that may have been missed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;: Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt;: Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt;: Evidence obtained from well-designed cohort or case&amp;ndash;control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt;: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt;: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /><FieldValue Value="Review of Published Meta-Analyses" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt;: Recommendations are based primarily on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt;: Recommendations are based primarily on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt;: Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines were reviewed and approved by the Board of Directors of the Society of Family Planning.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of recommendations (&lt;strong&gt;A, B, C&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Conclusions and Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Some serious, complex medical problems pose a dramatically increased risk for adverse health events during pregnancy. Early abortion care and effective postabortion care for women with such medical problems will reduce pregnancy-associated morbidity and mortality. To date, no Level A evidence supports clinical recommendations for care of women with medical conditions who are undergoing abortion. The authors offer guidance in the original guideline document on the basis of clinical experience combined with known features of coexisting conditions and abortion care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;On the basis of the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations are based primarily on good and consistent scientific evidence (&lt;strong&gt;Level A&lt;/strong&gt;):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;There is no Level A evidence to support the practice recommendations. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Recommendations are based primarily on limited or inconsistent scientific evidence (&lt;strong&gt;Level B&lt;/strong&gt;):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The dose of mifepristone should be increased above 200 mg when medical abortion is undertaken for women who are also being given inducers of the hepatic cytochrome p450 system. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In steroid-dependent conditions, mifepristone's antiglucocorticoid properties necessitate an increase in usual steroid doses. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Recommendations are based primarily on consensus and expert opinion (&lt;strong&gt;Level C&lt;/strong&gt;):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Women with stable, controlled hypertension, diabetes, or asthma can be safely managed in an outpatient setting. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital-based abortion is recommended for women with certain medical conditions (see table below). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with high-risk cardiac conditions do not require additional antibiotics for the prevention of infective endocarditis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical abortion is preferred for women who have a bleeding disorder or who are anticoagulated in the first trimester. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table. Indications for Referral to Hospital-Based Provider&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Table. Indications for Referral to Hospital-Based Provider&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Central Nervous System&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Vascular&amp;ndash;untreated aneurysm &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Space occupying lesions &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Renal Disease&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Impaired renal function (serum creatinine &amp;gt;2.5 mg/dL) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Hypertension&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Uncontrolled blood pressure (BP) (systolic BP &amp;gt;160 or diastolic BP &amp;gt;105) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Endocrine&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Uncontrolled hyperthyroidism, uncontrolled diabetes, pheochromocytoma &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Cardiac&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Congenital (cyanotic disease, right ventricular [RV] or left ventricular [LV] dilation, uncontrolled tachyarrhythmia) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Coronary disease (history of myocardial infarction, treatment angina) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cardiomyopathy (dilated, hypertrophic, history of peripartum cardiomyopathy) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Valvular disease (aortic stenosis [AS] peak gradient &amp;ge;60 mmHg, mitral stenosis [MS] valve area &amp;lt;1.5 cm&lt;sup&gt;2&lt;/sup&gt;, mitral regurgitation [MR] or aortic regurgitation [AR] with LV dilation) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Pulmonary&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Uncontrolled asthma &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Restrictive lung disease &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Pulmonary hypertension &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Rheumatological&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lupus flare &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lupus inhibitor requiring anticoagulation &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Gastrointestinal (GI)&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Hepatic disease elevated prothrombin time (PT) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Esophageal varices with history of bleeding &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Uncontrolled inflammatory bowel disease &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Hematological&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Severe anemia &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Sickle cell disease with a history of crisis &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Idiopathic thrombocytopenia purpura with active thrombocytopenia &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Thrombophilia requiring anticoagulation &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Oncology&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Counseling regarding treatment options and timing of abortion &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Gynecologic cancers restricting access to the uterus &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Transplant&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Significantly impaired renal function (creatinine &amp;gt;2.5 mg/dL) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;History of recent rejection &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poorly functioning transplanted organ &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Psychiatric&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Inability to obtain informed consent &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Inability to tolerate an outpatient procedure &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;History of suicide attempt &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt;: Recommendations are based primarily on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt;: Recommendations are based primarily on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt;: Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of first-trimester abortion in women with medical conditions&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;For all women seeking abortion, delays should be minimized because the safety of abortion is strongly related to gestational age, even in the first trimester. The mortality rate for women obtaining an abortion at &amp;le;8 weeks was 0.1 per 100,000 legal induced abortions, compared with 0.4 per 100,000 legal induced abortions at &amp;le;12 weeks. For women with medical problems, avoiding delays is particularly important because their condition may deteriorate with advancing pregnancy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical abortion for obese women may be associated with increased technical difficulty and, for second-trimester procedures, with adverse outcomes such as increased blood loss; prompt care is therefore important. Ventilation difficulties with deep sedation may be more common with obese patients. Consultation with an anesthesiologist may be helpful. One study demonstrated that rates of undesired outcomes following medication abortion, such as surgical interventions, were similar across all body mass index (BMI) categories, suggesting that medication abortion may be the better option for obese women. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When patients requiring anticoagulation medication(s) seek abortion, providers are faced with the clinical decision of whether to interrupt or modify therapy. Reversal of anticoagulation may decrease bleeding, but increase the risk of thromboembolism, particularly during pregnancy and especially with certain high-risk conditions (e.g., patients with cardiac valve replacement). Further, it may take several days to reverse anticoagulation, thereby delaying abortion. Women with a high risk of thrombosis maintained on warfarin may be transitioned to heparin, which can be held for surgery, and then warfarin may be restarted. This approach is time-consuming and complex. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients on antiplatelet therapies such as aspirin and clopidogrel, the risk of bleeding must be carefully weighed against the risk of coronary artery ischemic events. Patients on combination antiplatelet therapy (i.e., clopidogrel and aspirin) face an increased risk of systemic bleeding. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Methotrexate inhibits dihydrofolate reductase (DHFR), causing depletion of cofactors required for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis. Based on its pharmacological action, methotrexate should not be administered in patients with evidence of immunodeficiency, moderate to severe anemia, leukopenia or thrombocytopenia, active pulmonary disease, active peptic ulcer disease, clinically important hepatic dysfunction or clinically important renal dysfunction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For women with medical conditions, absolute and relative contraindications to medication abortion drugs preclude their use in certain patients. Current labeling precautions related to the safety of medication abortion regimens for women with chronic medical conditions reflect the lack of available data; such patients have been excluded from clinical trials. Some of the contraindications listed (chronic adrenal failure, inherited porphyria, long-term corticosteroid therapy) relate to pharmacologic properties of medication abortion drugs and associated known or theoretical implications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemorrhagic disorders and concurrent anticoagulation therapy are listed as contraindications on the product labeling for Mifeprex&amp;reg; (Danco, New York, NY, USA). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inherited porphyria is listed as a contraindication to mifepristone. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mifepristone undergoes hepatic and renal metabolism; therefore, it is logical to avoid administration in patients with severe hepatic impairment or renal failure, given the concern for drug accumulation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mifepristone medication abortion should be avoided in women with poorly controlled asthma on systemic glucocorticoid therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of ergot alkaloids is contraindicated for patients taking potent inhibitors of cytochrome P (CYP) 3A4 (which include protease inhibitors, azole antifungals and some macrolide antibiotics) and/or with hypertension. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Carboprost tromethamine is contraindicated in patients with active cardiac, pulmonary, renal, or hepatic disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in patients with thrombocytopenia or other preexisting platelet defects (e.g., von Willebrand disease), patients at risk of acute renal failure or gastrointestinal bleeding or patients with significant preexisting cardiovascular disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of combined hormonal contraception is usually contraindicated for women with evidence of vascular disease or end-organ damage. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This evidence-based review should guide clinicians, although it is not intended to dictate clinical care.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Guiahi M, Davis A, Society of Family Planning. First-trimester abortion in women with medical conditions. Contraception. 2012 Dec;86(6):622-30. [56 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23039921&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 Dec" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Society of Family Planning - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Society of Family Planning receives no direct support from pharmaceutical companies or other industries.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Maryam Guiahi, M.D., M.S., and Anne Davis, M.D., M.P.H&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Maryam Guiahi, M.D., M.S., and Anne Davis, M.D., M.P.H., report no significant relationships with industries relative to these guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.societyfp.org/_documents/resources/guidelines2012-2.pdf&quot; title=&quot;Society of Family Planning Web site&quot;&gt;Society of Family Planning Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on January 13, 2014. The information was verified by the guideline developer on February 10, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
